True Wealth Design
TNXP icon

True Wealth Design’s Tonix Pharmaceuticals TNXP Stock Holding History

True Wealth Design’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$702 Sell
72
-280
-80% -$3.3K ﹤0.01% 2035
2026
Q2 		$4.49K Buy
352
+306
+665% +$3.95K ﹤0.01% 1375
2026
Q1 		$633 Buy
+46
New +$708 ﹤0.01% 1961

Other funds holding TNXP

Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Acorn Wealth Advisors
Acorn Wealth Advisors Grand Blanc, Michigan $407M AUM 14.44% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
CNBT
Cornerstone National Bank & Trust Palatine, Illinois $309M AUM 7.69% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

True Wealth Design's TNXP Position: Q3 2026 in Review

True Wealth Design reduced its Tonix Pharmaceuticals (TNXP) stake by 80% in Q3 2026, selling an estimated $3.3K and leaving 72 shares worth $702. The position accounts for ﹤0.01% of the portfolio, ranked #2035.

True Wealth Design first reported a position in TNXP in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.49K in Q2 2026. 16 funds tracked by Wall St. Rank hold TNXP as of Q3 2026.

  • True Wealth Design held 72 shares of Tonix Pharmaceuticals worth $702 as of Q3 2026.
  • True Wealth Design sold 280 Tonix Pharmaceuticals shares in Q3 2026, an estimated $3.3K.
  • Tonix Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #2035 holding.
  • True Wealth Design first reported a position in Tonix Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • True Wealth Design's Tonix Pharmaceuticals position peaked at $4.49K in Q2 2026.
  • 16 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.